191 related articles for article (PubMed ID: 19393225)
1. Effect of dose and plasma concentration on liver uptake and pharmacologic activity of a 2'-methoxyethyl modified chimeric antisense oligonucleotide targeting PTEN.
Geary RS; Wancewicz E; Matson J; Pearce M; Siwkowski A; Swayze E; Bennett F
Biochem Pharmacol; 2009 Aug; 78(3):284-91. PubMed ID: 19393225
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and pharmacodynamics of an antisense phosphorothioate oligonucleotide targeting Fas mRNA in mice.
Yu RZ; Zhang H; Geary RS; Graham M; Masarjian L; Lemonidis K; Crooke R; Dean NM; Levin AA
J Pharmacol Exp Ther; 2001 Feb; 296(2):388-95. PubMed ID: 11160622
[TBL] [Abstract][Full Text] [Related]
3. Cross-species comparison of in vivo PK/PD relationships for second-generation antisense oligonucleotides targeting apolipoprotein B-100.
Yu RZ; Lemonidis KM; Graham MJ; Matson JE; Crooke RM; Tribble DL; Wedel MK; Levin AA; Geary RS
Biochem Pharmacol; 2009 Mar; 77(5):910-9. PubMed ID: 19056355
[TBL] [Abstract][Full Text] [Related]
4. Co-Administration of an Excipient Oligonucleotide Helps Delineate Pathways of Productive and Nonproductive Uptake of Phosphorothioate Antisense Oligonucleotides in the Liver.
Donner AJ; Wancewicz EV; Murray HM; Greenlee S; Post N; Bell M; Lima WF; Swayze EE; Seth PP
Nucleic Acid Ther; 2017 Aug; 27(4):209-220. PubMed ID: 28448194
[TBL] [Abstract][Full Text] [Related]
5. Comparing in vitro and in vivo activity of 2'-O-[2-(methylamino)-2-oxoethyl]- and 2'-O-methoxyethyl-modified antisense oligonucleotides.
Prakash TP; Kawasaki AM; Wancewicz EV; Shen L; Monia BP; Ross BS; Bhat B; Manoharan M
J Med Chem; 2008 May; 51(9):2766-76. PubMed ID: 18399648
[TBL] [Abstract][Full Text] [Related]
6. Phase I trial of ISIS 104838, a 2'-methoxyethyl modified antisense oligonucleotide targeting tumor necrosis factor-alpha.
Sewell KL; Geary RS; Baker BF; Glover JM; Mant TG; Yu RZ; Tami JA; Dorr FA
J Pharmacol Exp Ther; 2002 Dec; 303(3):1334-43. PubMed ID: 12438559
[TBL] [Abstract][Full Text] [Related]
7. Spinal distribution and metabolism of 2'-O-(2-methoxyethyl)-modified oligonucleotides after intrathecal administration in rats.
Butler M; Hayes CS; Chappell A; Murray SF; Yaksh TL; Hua XY
Neuroscience; 2005; 131(3):705-15. PubMed ID: 15730875
[TBL] [Abstract][Full Text] [Related]
8. Pharmacodynamics and subchronic toxicity in mice and monkeys of ISIS 388626, a second-generation antisense oligonucleotide that targets human sodium glucose cotransporter 2.
Zanardi TA; Han SC; Jeong EJ; Rime S; Yu RZ; Chakravarty K; Henry SP
J Pharmacol Exp Ther; 2012 Nov; 343(2):489-96. PubMed ID: 22915769
[TBL] [Abstract][Full Text] [Related]
9. Cross-species pharmacokinetic comparison from mouse to man of a second-generation antisense oligonucleotide, ISIS 301012, targeting human apolipoprotein B-100.
Yu RZ; Kim TW; Hong A; Watanabe TA; Gaus HJ; Geary RS
Drug Metab Dispos; 2007 Mar; 35(3):460-8. PubMed ID: 17172312
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic and Pharmacodynamic Investigations of ION-353382, a Model Antisense Oligonucleotide: Using Alpha-2-Macroglobulin and Murinoglobulin Double-Knockout Mice.
Shemesh CS; Yu RZ; Gaus HJ; Seth PP; Swayze EE; Bennett FC; Geary RS; Henry SP; Wang Y
Nucleic Acid Ther; 2016 Aug; 26(4):223-35. PubMed ID: 27031383
[TBL] [Abstract][Full Text] [Related]
11. Disposition and Pharmacokinetics of a GalNAc3-Conjugated Antisense Oligonucleotide Targeting Human Lipoprotein (a) in Monkeys.
Yu RZ; Gunawan R; Post N; Zanardi T; Hall S; Burkey J; Kim TW; Graham MJ; Prakash TP; Seth PP; Swayze EE; Geary RS; Henry SP; Wang Y
Nucleic Acid Ther; 2016 Dec; 26(6):372-380. PubMed ID: 27500733
[TBL] [Abstract][Full Text] [Related]
12. Inhaled p38alpha mitogen-activated protein kinase antisense oligonucleotide attenuates asthma in mice.
Duan W; Chan JH; McKay K; Crosby JR; Choo HH; Leung BP; Karras JG; Wong WS
Am J Respir Crit Care Med; 2005 Mar; 171(6):571-8. PubMed ID: 15557129
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of a tumor necrosis factor-alpha phosphorothioate 2'-O-(2-methoxyethyl) modified antisense oligonucleotide: comparison across species.
Geary RS; Yu RZ; Watanabe T; Henry SP; Hardee GE; Chappell A; Matson J; Sasmor H; Cummins L; Levin AA
Drug Metab Dispos; 2003 Nov; 31(11):1419-28. PubMed ID: 14570775
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic-pharmacodynamic modeling for reduction of hepatic apolipoprotein B mRNA and plasma total cholesterol after administration of antisense oligonucleotide in mice.
Shimizu R; Kitade M; Kobayashi T; Hori S; Watanabe A
J Pharmacokinet Pharmacodyn; 2015 Feb; 42(1):67-77. PubMed ID: 25376372
[TBL] [Abstract][Full Text] [Related]
15. Lipid nanoparticles improve activity of single-stranded siRNA and gapmer antisense oligonucleotides in animals.
Prakash TP; Lima WF; Murray HM; Elbashir S; Cantley W; Foster D; Jayaraman M; Chappell AE; Manoharan M; Swayze EE; Crooke ST
ACS Chem Biol; 2013 Jul; 8(7):1402-6. PubMed ID: 23614580
[TBL] [Abstract][Full Text] [Related]
16. Reduction of liver Fas expression by an antisense oligonucleotide protects mice from fulminant hepatitis.
Zhang H; Cook J; Nickel J; Yu R; Stecker K; Myers K; Dean NM
Nat Biotechnol; 2000 Aug; 18(8):862-7. PubMed ID: 10932156
[TBL] [Abstract][Full Text] [Related]
17. Comparative Characterization of Hepatic Distribution and mRNA Reduction of Antisense Oligonucleotides Conjugated with Triantennary N-Acetyl Galactosamine and Lipophilic Ligands Targeting Apolipoprotein B.
Watanabe A; Nakajima M; Kasuya T; Onishi R; Kitade N; Mayumi K; Ikehara T; Kugimiya A
J Pharmacol Exp Ther; 2016 May; 357(2):320-30. PubMed ID: 26907624
[TBL] [Abstract][Full Text] [Related]
18. Antitumor activity of antisense clusterin oligonucleotides is improved in vitro and in vivo by incorporation of 2'-O-(2-methoxy)ethyl chemistry.
Zellweger T; Miyake H; Cooper S; Chi K; Conklin BS; Monia BP; Gleave ME
J Pharmacol Exp Ther; 2001 Sep; 298(3):934-40. PubMed ID: 11504787
[TBL] [Abstract][Full Text] [Related]
19. Reduction of JNK1 expression with antisense oligonucleotide improves adiposity in obese mice.
Yu XX; Murray SF; Watts L; Booten SL; Tokorcheck J; Monia BP; Bhanot S
Am J Physiol Endocrinol Metab; 2008 Aug; 295(2):E436-45. PubMed ID: 18523126
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of G3139, a phosphorothioate oligodeoxynucleotide antisense to bcl-2, after intravenous administration or continuous subcutaneous infusion to mice.
Raynaud FI; Orr RM; Goddard PM; Lacey HA; Lancashire H; Judson IR; Beck T; Bryan B; Cotter FE
J Pharmacol Exp Ther; 1997 Apr; 281(1):420-7. PubMed ID: 9103525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
